Home | Multiple Myeloma Hub

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

COMy 2020

Multiple Myeloma Types

SUVmax is a new prognostic indicator for patients with newly diagnosed MM

A summary of a study by Anne-Victoire Michaud-Robert and colleagues, published in Cancers, which described the use of SUVmax to quantify glucose metabolism and predict survival...

Sep 29, 2020

New SLAMF7-targeted CAR T-cell therapy

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, University Hospital of Würzburg, Würzburg, DE, about...

Sep 29, 2020

| EBMT 2020

At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nicolaus Kröger, University...

Sep 25, 2020

| EBMT 2020

Priority review for ide-cel granted by the FDA

It has been announced that the U.S. Food and Drug Administration (FDA) have accepted for priority review the Biologics License Application for idecabtagene vicleucel (ide-cel, bb2121), for use in adult...

Sep 24, 2020

María-Victoria Mateos

" The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice. "

Featured Expert Opinion

Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),...

EBMT 2020

New SLAMF7-targeted CAR T-cell therapy

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, University...

Sep 29, 2020

| EBMT 2020

At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple...

Sep 25, 2020

| EBMT 2020

How can we predict responses to CAR T-cell therapies, such as bb2121?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke...

Sep 14, 2020

| EBMT 2020

Changing practice patterns in autologous transplantation at EBMT centers

During the Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Patrick Hayden...

Sep 11, 2020

| EBMT 2020

EHA 2020

CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

Interview with Co-Chair María-Victoria Mateos on updates from this year's virtual ASCO Annual Meeting and EHA...

Aug 19, 2020

| EHA 2020

Can you identify high-risk MM more effectively?

In this second article from the current editorial theme on high-risk MM, we summarize an outstanding session about high-risk MM held at the Virtual...

Aug 18, 2020

| EHA 2020

Predicting early relapse in patients with multiple myeloma

At the 25th European Hematology Association (EHA) Annual Congress, three posters outlined the latest advancements achieved by GIMEMA, the...

Aug 4, 2020

| EHA 2020

Results from the TOURMALINE-MM4 trial: Ixazomib for maintenance

During this year’s European Hematology Association (EHA) Annual Congress and the American Society of Clinical Oncology (ASCO) Annual...

Jul 31, 2020

| EHA 2020

Chromosomal aberrations

KRd plus auto-SCT induces high-quality durable responses in NDMM

The results of a phase II trial (NCT01816971) that investigated the addition of autologous stem cell transplantation (auto-SCT) to KRd...

Sep 23, 2020

The clinical significance of chromosome 1 abnormalities in newly diagnosed multiple myeloma

After our recent overview of common cytogenetic abnormalities associated with a higher risk of relapse, we...

Sep 9, 2020

Is dara + VTd the best induction treatment for high-risk patients with newly diagnosed MM?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...

Sep 3, 2020

| EBMT 2020

Tandem stem cell transplantation for newly diagnosed high-risk multiple myeloma

As part of this month’s editorial theme, the Multiple Myeloma Hub is focusing on the clinical outlook of high-risk...

Aug 24, 2020

| MM

Most Viewed

María-Victoria Mateos’s top 3 breakthroughs in transplant for myeloma

Why do we not see curative CAR T-cell therapy in MM (compared to DLBCL and ALL)?

How to treat triple-class refractory MM?

Is there an optimal time to deploy immunotherapies in multiple myeloma?

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

SUVmax is a new prognostic indicator for patients with newly diagnosed MM

Sep 29, 2020

Sep 29, 2020

| EBMT 2020

Sep 25, 2020

| EBMT 2020

Sep 24, 2020

María-Victoria Mateos

EBMT 2020

Sep 29, 2020

| EBMT 2020

Sep 25, 2020

| EBMT 2020

Sep 14, 2020

| EBMT 2020

Sep 11, 2020

| EBMT 2020

EHA 2020

Aug 19, 2020

| EHA 2020

Aug 18, 2020

| EHA 2020

Aug 4, 2020

| EHA 2020

Jul 31, 2020

| EHA 2020

Most Read

Chromosomal aberrations

Sep 23, 2020

Sep 9, 2020

Sep 3, 2020

| EBMT 2020

Aug 24, 2020

| MM

Most Viewed